



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003827 M 07/08/1978 45 Y

Referral Testing

Collected: 08/30/2023 08:49 Received: 08/30/2023 08:49

| Test Name | Result | Flag | Ref-Ranges | Units | Site |
|--|--------------|------|------------|-------|------|
| Calreticulin (CALR) Mutation Analysis | | | | | |
| Clinical Indication: | NA | | | | QCRL |
| Specimen Source: | WB | | | | QCRL |
| Block/Specimen ID: | NA | | | | QCRL |
| CALR Exon 9 Mutation | NOT DETECTED | | | | QCRL |
| Reference Range: NOT DETECTED | | | | | |
| Gene | . | | | | QCRL |
| Amino Acid | . | | | | QCRL |
| Mutation Frequency | . | | | | QCRL |
| Mutation Type | . | | | | QCRL |
| Exon | . | | | | QCRL |
| Nucleotide Change | . | | | | QCRL |
| Reference | . | | | | QCRL |
| Interpretation | SEE NOTE | | | | QCRL |

No mutation is detected in exon 9 of CALR. Insertions up to 30bp and deletions up to 52bp have been successfully detected by the assay.

Assay Details SEE NOTE QCRL

This PCR-based advanced sequencing assay interrogates DNA from leukocytes for the presence of mutations in exon 9 of calreticulin (CALR). The sensitivity of mutation detection is approximately 5% but may vary depending on the particular mutation type. Insertions up to 30bp and deletions up to 52bp have been successfully detected by the assay. Alterations outside of the tested areas of this gene will not be detected. Synonymous or known non-synonymous polymorphic changes (SNPs) are not reported. Frameshift mutations in this region of CALR are associated with myeloproliferative neoplasms (MPNs), particularly essential thrombocythemia (ET) and primary myelofibrosis (PMF). Results of this assay should be correlated with morphology and other laboratory testing for final diagnosis and classification. If this test is negative, additional testing that may be useful for workup of MPNs, depending on presenting hematologic features, includes BCR-ABL1 rearrangement (test code 91065 or 12070X) or mutational analysis of JAK2 V617F (polycythemia vera (PV)/ET/PMF, 92473), JAK2 exon 12 (PV, 92474), MPL (ET/PMF, 92476) or CSF3R (chronic neutrophilic leukemia, 92477). Residual material from this sample may be used except for BCR-ABL1 testing; call lab to add.

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

F230000008
WX0000003827
Printed D&T: 08/30/23 08:52

Ordered By: KAJAL SITWALA, MD, PhD
WX00000000002365

Kajal V. Sitwala, MD, PhD - Medical Director
Form: MM RL1
PAGE 1 OF 2



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003827 M 07/08/1978 45 Y

Referral Testing

Collected: 08/30/2023 08:49

Received: 08/30/2023 08:49

| <u>Test Name</u> | <u>Result</u> | <u>Flag</u> | <u>Ref-Ranges</u> | <u>Units</u> | <u>Site</u> |
|------------------|---------------|-------------|-------------------|--------------|-------------|
|------------------|---------------|-------------|-------------------|--------------|-------------|

DNA was aligned to GRCh37(hg19) for analysis and transcript ID
ENST00000316448 was used as reference for CALR sequence.

For additional information, please refer to
<http://education.QuestDiagnostics.com/faq/FAQ211>
(This link is being provided for informational/educational purposes
only.)

This test was developed and its analytical performance characteristics
have been determined by Quest Diagnostics Nichols Institute San Juan
Capistrano. It has not been cleared or approved by FDA. This assay has
been validated pursuant to the CLIA regulations and is used for
clinical purposes.

Test Performed at:

Quest Diagnostics Nichols Institute
33608 Ortega Highway

San Juan Capistrano, CA 92675-2042 I Maramica MD, PhD, MBA

Performing Site:

QCRL: QUEST DIAGNOSTICS REFERENCE LAB CAPISTRANO 33608 Ortega Highway San Juan Capistrano CA 92675

Reported Date: 2023.08.30 8:51 CALRA

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

F230000008
WX0000003827

Printed D&T: 08/30/23 08:52

Ordered By: KAJAL SITWALA, MD, PhD
WX00000000002365

Kajal V. Sitwala, MD, PhD - Medical Director

Form: MM RL1

PAGE 2 OF 2